You are not currently logged in.
Access JSTOR through your library or other institution:
Safety and Immunogenicity of Different Immunization Regimens of CVD 103-HgR Live Oral Cholera Vaccine in Soldiers and Civilians in Thailand
Pisit Su-Arehawaratana, Preecha Singharaj, David N. Taylor, Charles Hoge, Andrew Trofa, Krit Kuvanont, Sricharoen Migasena, Punnee Pitisuttitham, Yu Leung Lim, Genevieve Losonsky, James B. Kaper, Steven S. Wasserman, Stanley Cryz, Peter Echeverria and Myron M. Levine
The Journal of Infectious Diseases
Vol. 165, No. 6 (Jun., 1992), pp. 1042-1048
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30112187
Page Count: 7
You can always find the topics here!Topics: Vaccination, Soldiers, Dosage, Cholera, Antibodies, Civilian personnel, Cholera vaccine, Immunity, Immune response, Placebos
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Attenuated Vibrio cholerae oral vaccine CVD 103-HgR was well tolerated by 324 Thai soldiers and civilians. Most received a single 5 X 10⁸ cfu dose, while 40 each received one or two 5 X 10⁹ cfu doses. Vibriocidal antibody (the best correlate of immunity) seroconversion was lower in soldiers than civilians (P < .001). Increasing the vaccine dose to 5 X 10⁹ cfu raised the geometric mean titer (P < .001). A second 5 X 10⁹ cfu dose one week later did not notably increase seroconversions. Likelihood of seroconversion was inversely correlated with baseline vibriocidal titer (P < .001). CVD 103-HgR caused seroconversion in most subjects with baseline titers < 1:40, including 100% of civilians after one 5 X 10⁸ cfu dose, 79% of soldiers after one 5 X 10⁹ cfu dose, and 45% of soldiers after one 5 X 10⁸ cfu dose. In persons with elevated baseline titers, vibriocidal antibody seroconversion is not a sensitive measure of whether vaccine has boosted intestinal immunity; for such subjects, other measurements must be used. Study regimens in endemic areas should use a single 5 X 10⁹ cfu dose.
The Journal of Infectious Diseases © 1992 Oxford University Press